Volume 2, Issue 3, October 2023

View Volume 2, Issue 3, October 2023

Bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy for indolent lymphoma
The role of FDG-PET scanning and PET-adapted therapy in the primary treatment of Hodgkin lymphoma: A primer for clinicians
Monoclonal gammopathy of clinical and undetermined significance
Frontline treatment of aggressive B-cell lymphoma
Chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma: The evolving Canadian landscape

Published: 2023-11-07

Full Issue

Articles

Bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy for indolent lymphoma

Isabelle Fleury, MD, Eva Laverdure, MD

5-11
- PDF (en)
- PDF (fr)
The role of FDG-PET scanning and PET-adapted therapy in the primary treatment of Hodgkin lymphoma: A primer for clinicians

Michael Crump, MD, FRCPC

13-19
- PDF (en)
- PDF (fr)
Monoclonal gammopathy of clinical and undetermined significance

Alissa Visram, MD

22-26
- PDF (en)
- PDF (fr)
Frontline treatment of aggressive B-cell lymphoma

Shannon Murphy, MD

28-31
- PDF (en)
- PDF (fr)
Chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma: The evolving Canadian landscape

Sita Bhella, MD

33-38
- PDF (en)
- PDF (fr)